For the quarter ended September 2026, Biogen Inc. (BIIB Quick QuoteBIIB - Free Report) reported revenue of $2.8 billion, up 10.6% over the same period last year. EPS came in at $2.62, compared to $4.81 in the year-ago quarter.

The reported revenue represents a surprise of +8.06% over the Zacks Consensus Estimate of $2.59 billion. With the consensus EPS estimate being $2.06, the EPS surprise was +27.18%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Product- Rare Disease- SPINRAZA- United States: $246.4 million compared to the $165.03 million average estimate based on nine analysts. The reported number represents a change of +60.8% year over year.
• Revenue- Product- Multiple Sclerosis (MS)- Interferon- Rest of world: $75 million compared to the $75.42 million average estimate based on eight analysts. The reported number represents a change of -12.5% year over year.
• Revenue- Product- Multiple Sclerosis (MS)- Interferon- United States: $133.2 million compared to the $145.98 million average estimate based on eight analysts. The reported number represents a change of -17.4% year over year.
• Revenue- Product- Rare Disease- SPINRAZA- Rest of World: $214.2 million compared to the $215.49 million average estimate based on eight analysts. The reported number represents a change of -3% year over year.
• Revenue- Anti-CD20 therapeutic programs: $497.3 million compared to the $497.05 million average estimate based on 11 analysts. The reported number represents a change of +0.7% year over year.
• Revenue- Contract manufacturing, royalty and other revenue: $149.7 million versus $121.49 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -1% change.
• Revenue- Product- Multiple Sclerosis (MS)- Interferon- Total: $208.2 million versus $221.55 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a -15.7% change.
• Revenue- Product- Rare Disease- SPINRAZA- Total: $460.6 million compared to the $382.54 million average estimate based on nine analysts. The reported number represents a change of +23.2% year over year.
• Alzheimer's collaboration revenue: $68.4 million compared to the $69.34 million average estimate based on nine analysts. The reported number represents a change of +60.2% year over year.
• Revenue- Product- Biosimilars- BENEPALI- Total: $117.3 million compared to the $108.95 million average estimate based on eight analysts. The reported number represents a change of -3.8% year over year.
• Revenue- Product- Other- ZURZUVAE- Total: $84.4 million versus the eight-analyst average estimate of $76.39 million. The reported number represents a year-over-year change of +52.6%.
• Revenue- Product- Rare Disease- SKYCLARYS- Total: $178.2 million versus the eight-analyst average estimate of $166.93 million. The reported number represents a year-over-year change of +34.1%.

View all Key Company Metrics for Biogen here>>>

Shares of Biogen have returned +11.3% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.